QUEBEC CITY, Jan. 23, 2012 /CNW Telbec/ - Aeterna Zentaris Inc.
(NASDAQ: AEZS) (TSX: AEZ) (the "Company"), a late-stage drug
development company specialized in oncology and endocrine therapy,
announced today that, pursuant to its existing "At-the-Market" ("ATM")
Sales Agreement, dated June 29, 2011, with MLV & Co. LLC ("MLV"),
formerly McNicoll, Lewis & Vlak LLC, the Company is commencing a new
ATM issuance program under which it may, at its discretion, from time
to time during the term of the sales agreement, sell up to a maximum of
10,400,000 of its common shares through ATM issuances on the NASDAQ
Stock Market up to an aggregate amount of US$16.0 million. MLV will act
as sales agent for any sales made under the ATM. The common shares will
be sold at market prices prevailing at the time of the sale of common
shares, and, as a result, prices may vary.
In connection with the commencement of this ATM issuance program, the
Company has filed a prospectus supplement dated January 23, 2012 to its
U.S. shelf prospectus, dated July 15, 2010, forming part of its U.S.
registration statement on Form F-10 with the United States Securities
and Exchange Commission ("SEC") as well as a prospectus supplement to
its Canadian final base shelf prospectus dated July 15, 2010.
The U.S. shelf prospectus and the supplement thereto have been filed
with the SEC on the SEC's website (www.sec.gov) and the Canadian final base shelf prospectus and the supplement
thereto have been filed on the SEDAR website maintained by the Canadian
Securities Administrators at www.sedar.com. Alternatively, MLV will provide copies of the U.S. documents upon
request by contacting MLV & Co. LLC, Attention: Randy Billhardt, 1251
Avenue of the Americas, 41st Floor, New York, NY 10020, or by calling 212-580-5881, while copies of
the Canadian documents may be obtained by contacting the Company's
Investor Relations department directly by calling (418) 652-8525, ext.
This press release does not and shall not constitute an offer to sell or
the solicitation of an offer to buy any of the common shares, nor shall
there be any sale of the common shares in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of such state
About Aeterna Zentaris Inc.
Aeterna Zentaris is a late-stage oncology drug development company
currently investigating potential treatments for various cancers
including colorectal, multiple myeloma, endometrial, ovarian, prostate
and bladder cancer. The Company's innovative approach of "personalized
medicine" means tailoring treatments to a patient's specific condition
and to unmet medical needs. Aeterna Zentaris' deep pipeline is drawn
from its proprietary discovery unit providing the Company with constant
and long-term access to state-of-the-art therapeutic options. For more
information please visit www.aezsinc.com
SOURCE AETERNA ZENTARIS INC.
For further information:
Ginette Beaudet Vallières
Investor Relations Coordinator
(418) 652-8525 ext. 265
The Trout Group LLC
Director of Communications
(418) 652-8525 ext. 406